Brought to you by 
Asahi Kasei Pharma gets rights to Auxilium Pharma's Xiaflex
15 Mar 2016
Executive Summary
Auxilium Pharmaceuticals Inc. (products for the aging population) has granted Asahi Kasei Pharma Corp. (AKP) exclusive Japanese rights to Xiaflex (collagenase clostridium histolyticum) for Dupuytren’s contracture and Peyronie’s disease. AKP also has the right of first negotiation for exclusive rights to market Xiaflex in Japan for additional indications.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Asahi Kasei Pharma gets rights to Auxilium Pharma's Xiaflex
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice